A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients - Wikidata - wikimedia - TriplyDB

A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients

A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients

http://www.wikidata.org/entity/Q35760706

about

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.

P2860

Q34807259-A2788B7D-C601-41F6-87C2-AC92B80DC11F Q35811940-006682F8-C1E0-4239-94E6-4AFE3960CC4D Q36700499-0F15376A-AE8B-4CBA-9DBB-68153F9BA94F Q36715943-59F97AF4-6A5D-48DC-8331-E2CB303357ED Q36777599-98F8534E-13AD-47C6-AED0-6023F54C6764 Q37135382-32056648-8452-4332-80EF-5801B9C91CA5 Q37504482-29E802B6-3131-49D4-8C51-01550A23070B Q37624344-FD609C63-FCC0-43EF-B781-5B5D691BEF79 Q38374457-59205B0C-65E0-412F-A323-89803D981DBF Q38847841-65C98143-3777-48BD-823A-4291059C9972 Q40791419-637D344B-E888-40E4-868F-8E6A30369620 Q41653330-65985D37-19DD-4627-9241-B898E3B11913 Q43418954-5F9305A8-8373-412D-9EF9-0C47BAF5D3B4

P2860

A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients

http://www.wikidata.org/entity/Q35760706

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

A pilot pharmacologic biomarke ...... tic cell transplant recipients

@ast

A pilot pharmacologic biomarke ...... tic cell transplant recipients

@en

type

label

A pilot pharmacologic biomarke ...... tic cell transplant recipients

@ast

A pilot pharmacologic biomarke ...... tic cell transplant recipients

@en

prefLabel

A pilot pharmacologic biomarke ...... tic cell transplant recipients

@ast

A pilot pharmacologic biomarke ...... tic cell transplant recipients

@en

P1433

Q35760706-24144857-0068-46B4-A8C2-4432618B9B6E

P1476

Q35760706-9B156BE2-2E2D-4FF7-BED4-BBFD706FD95A

P2093

Q35760706-077D8A6C-05F1-4720-8787-E1D9B279D3CA

Q35760706-19F41F16-C4D2-4564-82B7-63D9FD221361

Q35760706-5994F10D-3853-4F04-8C0C-D9BB475A2A47

Q35760706-604851D4-3B23-4D30-80DE-F7D5A89A6016

Q35760706-8036A0C7-2E9A-4AE0-B7EC-5B31FF4722BC

Q35760706-AFA89800-B781-495F-90BF-1DF4183A1C68

P2860

Q35760706-074C2871-3EC4-48F6-92D4-22E735C46C95

Q35760706-0D43F56F-EDBD-4CFC-94D7-C187DB638699

Q35760706-1DFAB63A-D4B4-46C8-B646-AFE9C52655C3

Q35760706-1FBE75D6-9353-4C68-8686-712B591EF17A

Q35760706-21777A53-5951-4E62-8580-F1B271A9292D

Q35760706-2624F1C1-50A7-4B8E-88DA-B659F450C0D7

Q35760706-3F738C6D-4846-4B57-A767-13B13CF1D4DC

Q35760706-4E346EF9-65EF-479C-AFD4-A690F51774A0

Q35760706-6505D6D5-CC02-42B2-9D20-3285A7A239DC

Q35760706-66EFDFEC-10F1-4131-AE6A-65461C020A48

P2888

Q35760706-8F8EF997-5812-48D2-A6B2-4C9C8F4D3627

P304

Q35760706-B22D70FC-C69E-43AE-BDC3-DB58BC4806FC

P31

Q35760706-17FBADEB-D323-4CD8-866A-F3902CA37364

P356

Q35760706-882F2CE7-E482-4953-BA45-3723878FC2DD

P433

Q35760706-883CC41D-8E5C-4225-9A6E-AB9714849138

P478

Q35760706-C724C79E-1B79-4130-97C4-BF1D0FC9F784

P50

Q35760706-42AB33ED-8F37-4767-8C4B-27D66478597B

Q35760706-84DCD75D-5431-4C81-A205-6F02773CB9A7

P577

Q35760706-2447A012-C73E-4707-B537-7F502267787E

P5875

Q35760706-AF85C70F-6463-4C43-B56F-B7C0BB9263BD

P698

Q35760706-7977B308-4320-4205-BB06-1EBA936FE717

P921

Q35760706-30A01384-E8F8-46EF-B1BB-6BB24F08489B

Q35760706-C29B2FE4-8669-45CE-AB93-7C695EDE033B

P932

Q35760706-65684B4B-9005-43F9-8A71-896011810F08

P356

S00280-011-1736-3

P1433

Cancer Chemotherapy and Pharmacology

P1476

A pilot pharmacologic biomarke ...... tic cell transplant recipients

@en

P2093

Erica L Woodahl

http://www.w3.org/2001/XMLSchema#string

Jeannine S McCune

http://www.w3.org/2001/XMLSchema#string

Joanne Wang

http://www.w3.org/2001/XMLSchema#string

Paul V O'Donnell

http://www.w3.org/2001/XMLSchema#string

Shelly Heimfeld

http://www.w3.org/2001/XMLSchema#string

Terry Furlong

http://www.w3.org/2001/XMLSchema#string

P2860

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Cellular and clinical pharmacology of fludarabine.

Busulfan in hematopoietic stem cell transplantation

How I treat refractory acute GVHD.

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients

Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.

P2888

s00280-011-1736-3

P304

263-272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-011-1736-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Hans Joachim Deeg

P577

2011-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51630636

http://www.w3.org/2001/XMLSchema#string

P698

21909959

http://www.w3.org/2001/XMLSchema#string

P921

fludarabine phosphate

P932

3280823

http://www.w3.org/2001/XMLSchema#string